

Appl. No. : 10/644,277  
Filed : August 19, 2003

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) An isolated human monoclonal antibody that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.

2. (Previously presented) The antibody of Claim 1, further comprising a light chain polypeptide having the sequence of SEQ ID NO.:64.

3.-40. (Cancelled)

~~3A1.~~ (Currently amended) An isolated antibody immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 1.

~~4A2.~~ (Withdrawn previously presented) A method for assaying the level of monocyte chemo-attractant protein (MCP-1) in a patient sample, comprising:

contacting the anti-MCP-1 antibody of Claim 1 with the patient sample; and  
detecting the level of MCP-1 in the patient sample.

~~5A3.~~ (Withdrawn) A method according to Claim ~~42~~, wherein the patient sample is blood.

~~6A4.~~ (Currently amended) A composition, comprising the antibody or fragment thereof of Claim 1, and a pharmaceutically acceptable carrier.

~~7A5.~~ (Withdrawn amended) A method of effectively treating a neoplastic disease, comprising:

selecting an animal in need of treatment for a neoplastic disease; and  
administering to said animal a therapeutically effective dose of the antibody of Claim 1.

~~8A6.~~ (Withdrawn amended) The method of Claim ~~45~~, wherein said neoplastic disease is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and prostrate prostate cancer.

47. (Withdrawn amended) A method of effectively treating inflammatory conditions, comprising:

selecting an animal in need of treatment for an inflammatory condition; and  
administering to said animal a therapeutically effective dose of the antibody of Claim 1.

Appl. No. : 10/644,277  
Filed : August 19, 2003

48. (Withdrawn) The method of Claim 47, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, and multiple sclerosis.

49. (Cancelled)

50. (Cancelled)

9 ~~51~~. (Currently amended) An isolated human monoclonal antibody that binds to the sequence ISVQRLASYRRITSSK (SEQ ID NO.: 150).

52. (Cancelled)

10 ~~53~~. (Previously presented) A method of manufacturing the antibody of Claim 1, comprising:

immunizing a mammal with a synthetic peptide of MCP-1;

recovering a lymphatic cell that expresses the antibody of Claim 1 from the immunized mammal; and

fusing the lymphatic cell with a myeloid-type cell to prepare a hybridoma cell that produces the antibody of Claim 1.

11 ~~54~~. (New) The antibody of Claim 1, wherein said antibody is conjugated to a therapeutic agent.

12 ~~55~~. (New) The antibody of Claim ~~54~~, wherein said therapeutic agent is a toxin.

13 ~~56~~. (New) The antibody of Claim ~~55~~, wherein said toxin is an immunotoxin.

14 ~~57~~. (New) The antibody of Claim ~~54~~, wherein said therapeutic agent is a chemotherapeutic agent.

15 ~~58~~. (New) The antibody of Claim ~~57~~, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

16 ~~59~~. (New) The antibody of Claim ~~54~~, wherein said therapeutic agent is a steroid.

17 ~~60~~. (New) The antibody of Claim ~~54~~, wherein said therapeutic agent is a radioisotope.

18 ~~61~~. (New) The antibody of Claim ~~60~~, wherein said radioisotope is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ ,  $^{125}\text{In}$ , and  $^{131}\text{I}$ .

19 ~~62~~. (New) The antibody of Claim ~~51~~, wherein said antibody is conjugated to a therapeutic agent.

20 ~~63~~. (New) The antibody of Claim ~~62~~, wherein said therapeutic agent is a toxin.

Appl. No. : 10/644,277  
Filed : August 19, 2003

21-64. (New) The antibody of Claim <sup>20</sup>63, wherein said toxin is an immunotoxin.

22-65. (New) The antibody of Claim <sup>20</sup>63, wherein said therapeutic agent is a chemotherapeutic agent.

23-66. (New) The antibody of Claim <sup>22</sup>65, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

24-67. (New) The antibody of Claim <sup>22</sup>65, wherein said therapeutic agent is a steroid.

25-68. (New) The antibody of Claim <sup>22</sup>65, wherein said therapeutic agent is a radioisotope.

26-69. (New) The antibody of Claim <sup>25</sup>68, wherein said radioisotope is selected from the group consisting of <sup>3</sup>H, <sup>14</sup>C, <sup>15</sup>N, <sup>35</sup>S, <sup>90</sup>Y, <sup>99</sup>Tc, <sup>111</sup>In, <sup>125</sup>In, and <sup>131</sup>I.

27-70. (New) The antibody of Claim 1, wherein said antibody neutralizes the activity of MCP-1.

28-71. (New) The antibody of Claim <sup>3</sup>71, wherein said antibody neutralizes the activity of MCP-1.

29-72. (New) The antibody of Claim <sup>9</sup>71, wherein said antibody neutralizes the activity of MCP-1.

30-73. (New) The antibody of Claim 1, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.

31-74. (New) The antibody of Claim <sup>30</sup>73, wherein said dissociation constant is 3.3 pM.

32-75. (New) The antibody of Claim <sup>31</sup>71, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.

33-76. (New) The antibody of Claim <sup>32</sup>75, wherein said dissociation constant is 3.3 pM.

34-77. (New) The antibody of Claim <sup>9</sup>71, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.

35-78. (New) The antibody of Claim <sup>34</sup>77, wherein said dissociation constant is 3.3 pM.

36-79. (New) An isolated human monoclonal antibody binding fragment that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.

37-80. (New) The antibody binding fragment of Claim <sup>36</sup>79, further comprising a light chain polypeptide having the sequence of SEQ ID NO.: 64.

38-81. (New) The antibody binding fragment of Claim <sup>36</sup>79, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, and F<sub>v</sub>.

Appl. No. : 10/644,277  
Filed : August 19, 2003

36

39,82. (New) The antibody binding fragment of Claim 29, wherein said fragment is conjugated to a therapeutic agent.